Latest Development Pipeline News

AGL Energy tightens its FY26 earnings outlook, buoyed by strong operational performance and strategic investments in batteries and gas peaking assets amid rising electricity demand driven by data centres and electrification.

Redcastle Resources is accelerating its shift from exploration to production, with mining operations set to start by late May 2026 under a capital-light joint venture with BML Ventures.

Dexus has partnered with Boral to develop a massive 2.5 million square metre logistics precinct in Melbourne’s west, aiming to create Australasia’s largest institutionally held industrial hub.

Stellar Resources has raised $22.1 million through a placement led by Metals X, boosting its cash reserves to $33 million and setting the stage for key feasibility studies at Heemskirk.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Eden Innovations has expanded its EdenCrete Pz7 installations across North America, launched a new defence-focused division EdenShield, and eliminated costly debt, positioning for growth with a $4 million capital raise.

Reach Resources has boosted its Blue Heaven gold resource by roughly 30% to 80,000 ounces, supported by strong metallurgical results and a newly granted mining lease, while progressing a $3.15 million rights issue to fund further exploration and development.

Stockland reports strong leasing growth and development momentum in 3Q26, highlighting new data centre and land lease partnerships while maintaining FY26 guidance.

Orbital Corporation advances its UAV engine production and hybrid propulsion technology while managing a $0.5 million net cash outflow in Q1 2026, supported by a $43 million business pipeline and new international contracts.

Prodigy Gold has boosted the indicated resource at its Hyperion Gold Deposit by 70%, lifting total resources to 454,000 ounces and progressing key mining approvals and joint ventures.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Image Resources delivered a solid first quarter at its Atlas project with production and sales within guidance, operating costs under forecast, and secured a six-month debt repayment holiday. Development advances on multiple mineral sands projects and maiden gold resource drilling is underway.